Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Insufficient Data" Linked To Most NDI Notification Failures At FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA rejects nearly 75% of new dietary ingredient notifications, with failure to provide sufficient ingredient identity or supporting data the most common reasons for rejection, says American Herbal Products Association President Michael McGuffin.

You may also be interested in...



Embria Studies FDA Expectations Before Successful EpiCor NDI

FDA’s formal acknowledgment of Embria’s NDI notification for EpiCor comes after the firm called FDA early in the process to discuss the pending notification and worked to understand the agency’s expectations fully. Kevin Boot, Embria’s regulatory counsel, recommends simple notifications that are “readable by everyone.”

Embria Studies FDA Expectations Before Successful EpiCor NDI

FDA’s formal acknowledgment of Embria’s NDI notification for EpiCor comes after the firm called FDA early in the process to discuss the pending notification and worked to understand the agency’s expectations fully. Kevin Boot, Embria’s regulatory counsel, recommends simple notifications that are “readable by everyone.”

NDI Needed In Absence Of "Concrete Evidence" Of Prior Sale – Attorney

Until FDA issues new dietary ingredient notification guidance, a company must consider several factors when deciding whether an NDI is necessary, an attorney says.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel